We believe that our study will provide a basis for development of GREB1 as a novel biomarker in combination with ER to better identify breast cancer patients who will benefit from tamoxifen therapy and those who will likely develop resistance to endocrine therapy. The gene discussed is ESR1; the disease is breast cancer.